CytoSorbents Corporation (NASDAQ:CTSO) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET
Company Participants
Michelle Almonte - Executive Assistant to CEO
Phillip Chan - Chief Executive Officer
Kathleen Bloch - Chief Financial Officer
Christian Steiner - EVP of Sales and Marketing and Managing Director of CytoSorbents Europe GmbH
Efthymios Deliargyris - Chief Medical Officer
Vincent Capponi - Chief Operating Officer and President
Christopher Cramer - VP of Business Development
Conference Call Participants
Zachary Weiner - Jefferies
Sean Lee - H.C. Wainwright
Operator
Good day, and welcome to the CytoSorbents Corporation Third Quarter 2022 Earnings Conference Call. Today's call is being recorded at the request of the company. [Operator Instructions]
At this time, I'd like to turn the conference over to Michelle Almonte. Please go ahead.
Michelle Almonte
Thank you, and good afternoon. Following the formal remarks today, we will open the call for your questions. Please be advised that the call will be recorded at the company's request. Joining me today from the company are Dr. Phillip Chan, Chief Executive Officer; Vincent Capponi, Chief Operating Officer and President; Kathleen Bloch, Chief Financial Officer; Dr. Efthymios Deliargyris, Chief Medical Officer; Dr. Christian Steiner, Executive Vice President of Sales and Marketing and Managing Director of CytoSorbents Europe GmbH; and Christopher Cramer, VP of Business Development.
Before I turn the call over to Dr. Chan, I'd like to remind listeners that during the call, management's prepared remarks may contain forward-looking statements, which are subject to risks and uncertainties. Management may make additional forward-looking statements in response to your questions today. Therefore, the company claims protection under safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Actual results may differ from results discussed today and therefore we refer you to a more detailed discussion of these risks and uncertainties in the company's filings with the SEC. Any projections as to the company's future performance represented by management include estimates today, as of November 3, 2022 and we assume no obligation to update these projections in the future as market conditions change.
During today's call, we will have an overview presentation covering the operating and financial highlights for the third quarter by management. Following that presentation, we will open the line to your questions during the live Q&A session with the rest of the management team.
At this time, it's now my pleasure to turn the call over to Dr. Phillip Chan.